Viking Therapeutics, Inc. (VKTX)
VKTX Stock Price Chart
Explore Viking Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VKTX price movements and trends.
VKTX Company Profile
Discover essential business fundamentals and corporate details for Viking Therapeutics, Inc. (VKTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Apr 2015
Employees
45.00
CEO
Brian Lian
Description
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
VKTX Financial Timeline
Browse a chronological timeline of Viking Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$1.21.
Earnings released on 29 Apr 2026
EPS came in at -$1.37 falling short of the estimated -$1.01 by -35.64%.
Earnings released on 11 Feb 2026
EPS came in at -$1.38 falling short of the estimated -$0.89 by -55.06%.
Earnings released on 22 Oct 2025
EPS came in at -$0.81 falling short of the estimated -$0.70 by -15.71%.
Earnings released on 23 Jul 2025
EPS came in at -$0.58 falling short of the estimated -$0.44 by -31.82%.
Earnings released on 23 Apr 2025
EPS came in at -$0.41 falling short of the estimated -$0.34 by -20.59%.
Earnings released on 5 Feb 2025
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%.
Earnings released on 23 Oct 2024
EPS came in at -$0.22 surpassing the estimated -$0.24 by +8.33%.
Earnings released on 24 Jul 2024
EPS came in at -$0.20 surpassing the estimated -$0.26 by +23.08%.
Earnings released on 24 Apr 2024
EPS came in at -$0.26 surpassing the estimated -$0.27 by +3.70%.
Earnings released on 7 Feb 2024
EPS came in at -$0.25 matching the estimated -$0.25, while revenue for the quarter reached $436.00k .
Earnings released on 25 Oct 2023
EPS came in at -$0.23 falling short of the estimated -$0.22 by -4.55%.
Earnings released on 26 Jul 2023
EPS came in at -$0.19 surpassing the estimated -$0.21 by +9.52%.
Earnings released on 26 Apr 2023
EPS came in at -$0.25 falling short of the estimated -$0.24 by -4.17%.
Earnings released on 8 Feb 2023
EPS came in at -$0.26 falling short of the estimated -$0.23 by -13.04%.
Earnings released on 26 Oct 2022
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.
Earnings released on 27 Jul 2022
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%.
Earnings released on 27 Apr 2022
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%.
Earnings released on 9 Feb 2022
EPS came in at -$0.16 surpassing the estimated -$0.19 by +15.79%.
Earnings released on 3 Nov 2021
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%.
Earnings released on 28 Jul 2021
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%.
VKTX Stock Performance
Access detailed VKTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
